Application of the radioreceptor assay for human chorionic gonadotropin in pregnancy testing  and management of trophoblastic disease.
A commercially prepared radioreceptor assay (RRA) for human chorionic gonadotropin (hCG) has been evaluated as a pregnancy test and in a quantitative assay to follow patients with hydatidiform mole. The RRA demonstrated almost 100% agreement in comparison with radioimmunoassay (RIA) and urinary hCG tests. In the quantitative assay, a limiting reliable concentration of 70 mIU/ml of hCG in serum could be obtained. Extremely good correlation was achieved between the RRA and RIA test for hCG in 2 patients with hydatidiform mole over a span of 3 months of followup after evacuation of the mole. The usefulness of the RRA as a replacement of RIA tests for hCG is discussed.
D006063:Chorionic Gonadotropin / Q000276:immunology*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000276:immunology / Q000378:metabolism; D007986:Luteinizing Hormone / Q000276:immunology; D011247:Pregnancy; D011259:Pregnancy Tests, Immunologic; D011863:Radioimmunoassay; D011869:Radioligand Assay; D014328:Trophoblastic Neoplasms / Q000276:immunology / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000276:immunology / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D007986:Luteinizing Hormone